Ernexa Therapeutics Inc. (ERNA) Operating income 2016–2025
Ernexa Therapeutics Inc. (ERNA) annual operating income history from SEC filings — each fiscal year as reported.
-$9.3MFY2025 · since FY2016: -$2.3M → -$9.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$9.3M | +40.5% |
| FY2024 | -$15.7M | +25.8% |
| FY2023 | -$21.1M | +36.4% |
| FY2022 | -$33.2M | +70.8% |
| FY2021 | -$113.7M | -1469.2% |
| FY2020 | -$7.2M | -311.4% |
| FY2019 | -$1.8M | -968.0% |
| FY2018 | $203,000 | +114.5% |
| FY2017 | -$1.4M | +38.5% |
| FY2016 | -$2.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ERNA financial trends
ERNA RevenueERNA Net incomeERNA Net marginERNA Gross profitERNA Gross marginERNA Operating marginERNA Operating cash flowERNA Free cash flowERNA Capital expendituresERNA Return on equityERNA Stock buybacksERNA Dividends paidERNA Total assetsERNA Total liabilitiesERNA Shareholders’ equityERNA overview →